145 related articles for article (PubMed ID: 31368150)
21. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
[TBL] [Abstract][Full Text] [Related]
23. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.
Ren J; Peng Z; Yang K
Gynecol Oncol; 2008 Aug; 110(2):162-7. PubMed ID: 18495223
[TBL] [Abstract][Full Text] [Related]
24. Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours.
Chang C; Chen J; Chen WA; Ho SP; Liou WS; Chiang AJ
J Obstet Gynaecol; 2017 Feb; 37(2):233-237. PubMed ID: 27922289
[TBL] [Abstract][Full Text] [Related]
25. Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors.
Bendifallah S; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
Am J Obstet Gynecol; 2014 Dec; 211(6):637.e1-6. PubMed ID: 24949545
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors.
Suri A; Carter EB; Horowitz N; Denslow S; Gehrig PA
Gynecol Oncol; 2013 Nov; 131(2):321-4. PubMed ID: 23994106
[TBL] [Abstract][Full Text] [Related]
28. Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study.
Poncelet C; Fauvet R; Boccara J; Daraï E
Ann Surg Oncol; 2006 Apr; 13(4):565-71. PubMed ID: 16491337
[TBL] [Abstract][Full Text] [Related]
29. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study.
Kajiyama H; Suzuki S; Yoshikawa N; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():131-136. PubMed ID: 30685661
[TBL] [Abstract][Full Text] [Related]
30. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT).
Karlsen NMS; Karlsen MA; Høgdall E; Nedergaard L; Christensen IJ; Høgdall C
Gynecol Oncol; 2016 Jul; 142(1):50-53. PubMed ID: 27168006
[TBL] [Abstract][Full Text] [Related]
31. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I
Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897
[TBL] [Abstract][Full Text] [Related]
32. Nationwide population-based study of prevalence and trend of borderline ovarian tumors in the Republic of Korea.
Ouh YT; Kang D; Kim H; Lee JK; Hong JH
Sci Rep; 2021 May; 11(1):11158. PubMed ID: 34045639
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic factors and fertility outcomes of borderline ovarian tumors after conservative surgery].
Tao T; Cao DY; Yang JX; Shen K; Lang JH; Guo LN
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Oct; 32(5):488-92. PubMed ID: 21050550
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
35. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
36. Epithelial ovarian carcinoma of low malignant potential.
Darai E; Teboul J; Walker F; Benifla JL; Meneux E; Guglielmina JN; Pennehouat G; Renolleau C; Sebban E; Madelenat P
Eur J Obstet Gynecol Reprod Biol; 1996 Jun; 66(2):141-5. PubMed ID: 8735736
[TBL] [Abstract][Full Text] [Related]
37. Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery.
Delle Marchette M; Ceppi L; Andreano A; Bonazzi CM; Buda A; Grassi T; Giuliani D; Sina F; Lamanna M; Bianchi T; Lissoni AA; Landoni F; Valsecchi MG; Fruscio R
Eur J Cancer; 2019 Apr; 111():61-68. PubMed ID: 30826658
[TBL] [Abstract][Full Text] [Related]
38. Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study.
Lundberg FE; Johansson ALV; Rodriguez-Wallberg K; Gemzell-Danielsson K; Iliadou AN
Eur J Epidemiol; 2019 Nov; 34(11):1093-1101. PubMed ID: 31377935
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors for Recurrence After Fertility-Preserving Surgery in Patients With Borderline Ovarian Tumors: A Systematic Review and Meta-analysis of Observational Studies.
Jiao X; Hu J; Zhu L
Int J Gynecol Cancer; 2017 Nov; 27(9):1833-1841. PubMed ID: 28816706
[TBL] [Abstract][Full Text] [Related]
40. The Evaluation of Risk Factors Associated With Relapse and Recurrence of Borderline Ovarian Tumors With Long-Term Follow-up.
Sobiczewski P; Kupryjanczyk J; Michalski W; Śpiewankiewicz B
Int J Gynecol Cancer; 2016 Jul; 26(6):1053-61. PubMed ID: 27177283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
